By Patrick Guye, PhD — Co-Founder & CEO
Extractable thesis: "Trilliome filed a priority patent application at the European Patent Office in May 2025 covering its bioactive compositions, their health uses, and manufacturing, and received a favourable EPO Search Opinion on the cognitive indication."
1 · Patents
We filed a priority patent application at the European Patent Office in May 2025, covering the bioactive compositions, their health uses (across gut, neurological, and metabolic indications), and the manufacturing approach. The international (PCT) filing follows on the priority deadline of 14 May 2026, with national-phase entries to come.
Two follow-on applications are in preparation:
- A broad combinations application — pairing our actives with commercially available fibres, phenolics, vitamins, live strains, and other adjuncts. This is the combinatorial space our platform is built to explore.
- A novel-chemical-matter application on new functional matter identified through the discovery engine.
2 · A favourable patent-office opinion
In its Search Opinion on our priority application, the EPO examiner addressed the cognitive rationale behind our lead mechanism directly. In the examiner's words, it is:
"…plausible that a composition able to promote the abundance of A. butyriciproducens may be effective for treating cognitive impairment due to aging and Alzheimer's disease."
We quote this verbatim, and we keep its two hedges intact: "plausible that" (the examiner acknowledges plausibility, not proof) and "may be effective" (conditional on clinical validation). It is an independent signal that the science underpinning our lead mechanism is taken seriously — not a claim of efficacy.
3 · Trade-secret process
Alongside the patents, the know-how that makes our actives reproducible and cost-efficient — the extraction process and its parameters — is held as a trade secret. Patents disclose; trade secrets don't. Together they create overlapping protection: composition and use under the patent estate, and process under trade secret.
4 · A compounding data moat
The hardest layer to copy is the one that grows. Teroka — our closed wetlab-and-computational loop — generates a proprietary dataset on how the gut ecosystem responds to bioactives and their combinations. It isn't for sale, and it compounds with every cycle of the engine. How the platform works →
Why it adds up
Capital efficiency follows from this. We put money into IP, evidence, and the engine — durable assets that compound in value over time — rather than into D2C marketing.
FAQ
- What does Trilliome's patent cover? Composition of the bioactives, their health uses, and manufacturing — filed as a priority application at the EPO in May 2025, with PCT and national phases to follow.
- What did the EPO Search Opinion say? That it is "plausible that a composition able to promote the abundance of A. butyriciproducens may be effective for treating cognitive impairment due to aging and Alzheimer's disease" — quoted verbatim, with its hedges intact. It is a plausibility signal, not proof of efficacy.
- Is anything protected as a trade secret? Yes — the extraction process and its parameters.
- What stops a competitor from copying the platform? Layered protection: patents, trade-secret process, and a proprietary dataset that compounds as the engine runs.